mRNA Vaccine Against Japanese Encephalitis Virus Genotype IV Protects Against Lethal Infection
Viruses · 28.01.2026 · 18 (2) · 171
DOI: 10.3390/v18020171 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 28.01.2026. Verfasst von Abigail L Cox und 10 weiteren Autor:innen. Beteiligte Einrichtung: Infection and Inflammation Department, QIMR Berghofer, Brisbane, QLD 4029, Australia. Hauptthemen laut MEDLINE: Encephalitis, Japanese, Encephalitis Virus, Japanese, Japanese Encephalitis Vaccines, mRNA Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MRFF (Department of Industry, Science, Energy and Resources), Brazil Family Foundation, National Health and Medical Research Council (Australia).
Abstract (Originalsprache)
In 2022, Australia saw an unprecedented outbreak of Japanese encephalitis virus genotype IV (JEV GIV). The outbreak involved 42 human cases with 7 fatalities, as well as affecting >80 pig farms in New South Wales and Queensland. Herein, we designed, constructed, and tested two JEV GIV mRNA vaccines encoding prME, which provided protection against a lethal JEV GIV challenge in an Ifnar-/- mouse model. The vaccines were not codon optimized and included either the Native (full-length) or a Shorter signal peptide, with the latter missing the N-terminal n-region. Two vaccinations with 5 µg of the Shorter vaccine provided neutralizing antibody responses that were significantly lower but overlapped with those seen after vaccination with Imojev, a live attenuated vaccine approved for use in humans. Both mRNA vaccines provided approximately a five to six log reduction in viremia, ≥80% protection against overt disease and weight loss, and mortality. The paper illustrates in-country mRNA vaccine generation in response to a local outbreak, with JEV mRNA vaccines potentially emerging to be easier to manufacture, cheaper, and more suitable for immunocompromised individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infection and Inflammation Department, QIMR Berghofer, Brisbane, QLD 4029, Australia.
- Faculty of Health, Medicine and Behavioural Sciences, University of Queensland, St. Lucia, QLD 4072, Australia.
- Nanomedicine Biofoundry, Institute for Biomedicine and Glycomics, Griffith University, Southport, QLD 4215, Australia.
- Southern RNA Pty Ltd., 16 Nexus Way, Southport, QLD 4215, Australia.
- School of Chemistry and Molecular Biosciences, University of Queensland, St. Lucia, QLD 4072, Australia.
- GVN Center of Excellence, Australian Infectious Disease Research Centre, Brisbane, QLD 4029 and 4072, Australia.
ORCID-Profile: Abigail L Cox, Wilson Nguyen, Lucy Wales-Earl
Förderung
- MRFF (Department of Industry, Science, Energy and Resources)
- Brazil Family Foundation
- National Health and Medical Research Council (Australia)
- University of Queensland
- National Health and Medical Research Council (NHMRC) of Australia
Zitieren
APA
Cox, A. L., Nguyen, W., Wales-Earl, L., Tang, B., Yan, K., Peters, J., Khromykh, A. A., Tropée, R., McMillan, N. A. J., Suhrbier, A., & Rawle, D. J. (2026). mRNA Vaccine Against Japanese Encephalitis Virus Genotype IV Protects Against Lethal Infection. Viruses, 18(2), 171. https://doi.org/10.3390/v18020171
Vancouver
Cox AL, Nguyen W, Wales-Earl L, Tang B, Yan K, Peters J, et al. mRNA Vaccine Against Japanese Encephalitis Virus Genotype IV Protects Against Lethal Infection. Viruses. 2026;18(2):171. doi:10.3390/v18020171
BibTeX
@article{Cox2026,
author = {Cox, Abigail L and Nguyen, Wilson and Wales-Earl, Lucy and Tang, Bing and Yan, Kexin and Peters, Jonathan and Khromykh, Alexander A and Tropée, Romain and McMillan, Nigel A J and Suhrbier, Andreas and Rawle, Daniel J},
title = {mRNA Vaccine Against Japanese Encephalitis Virus Genotype IV Protects Against Lethal Infection},
journal = {Viruses},
year = {2026},
volume = {18},
number = {2},
pages = {171},
doi = {10.3390/v18020171}
}
EUVIMED